Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | CTSD | P07339 | 2/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567423 | 1.00 | BACE1 (0.40) | BACE1CTSDMMESMN1; SMN2ALDH1A1 | |
| SCHEMBL3785072 | 0.96 | SMN1; SMN2 (0.41) | BACE1MMESMN1; SMN2ALDH1A1ENPEP | |
| SCHEMBL30494781 | 0.96 | SMN1; SMN2 (0.41) | BACE1MMESMN1; SMN2ALDH1A1ENPEP | |
| SCHEMBL30494619 | 0.96 | SMN1; SMN2 (0.41) | BACE1MMESMN1; SMN2ALDH1A1ENPEP | |
| SCHEMBL3785069 | 0.96 | SMN1; SMN2 (0.41) | BACE1MMESMN1; SMN2ALDH1A1ENPEP | |
| SCHEMBL30462197 | 0.92 | PDCD1LG2 (0.44) | BACE1CTSDMMEENPEPDPP4 | |
| SCHEMBL29374714 | 0.90 | BACE1 (0.48) | BACE1CTSDMMEENPEPDPP4 | |
| SCHEMBL10377178 | 0.90 | DPP4 (0.38) | BACE1CTSDENPEPDPP4DPP8 | |
| SCHEMBL31720879 | 0.89 | ENPEP (0.48) | CTSDALDH1A1ENPEP | |
| SCHEMBL31181173 | 0.89 | ENPEP (0.44) | BACE1CTSDENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122301-A1 | CD25 ANTIBODIES | IBIO, INC. | 2025-04-17 | — | — | US | disclosed |
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | UNIVERSITY OF WASHINGTON | 2025-04-03 | — | — | US | disclosed |
| US-12239744-B2 | Surfactant peptide nanostructures and uses thereof in drug delivery | 3-D MATRIX, LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| US-11938341-B2 | Method and apparatus for fast influence matrix generation | SIEMENS HEALTHINEERS INTERNATIONAL AG (CH) | 2024-03-26 | — | — | US | disclosed |
| US-20230191150-A1 | METHOD AND APPARATUS FOR FAST INFLUENCE MATRIX GENERATION | SIEMENS HEALTHINEERS INTERNATIONAL AG (CH) | 2023-06-22 | — | — | US | disclosed |
| EP-4197594-A1 | METHOD AND APPARATUS FOR FAST INFLUENCE MATRIX GENERATION | Siemens Healthineers International AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20220249392-A1 | SURFACTANT PEPTIDE NANOSTRUCTURES AND USES THEREOF IN DRUG DELIVERY | 3-D MATRIX, LTD. (JP) | 2022-08-11 | — | — | US | disclosed |
| US-11324703-B2 | Surfactant peptide nanostructures and uses thereof in drug delivery | 3-D MATRIX, LTD. (JP) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250111889-A1 | DE NOVO DESIGNED MACROCYCLIC OLIGOAMIDES | DHFR, CCNH, ODC1 | BACE1 4382/4885CTSD 1288/4885MME 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.